Share chart AstraZeneca PLC
Extended chart
Simple chart
About AstraZeneca PLC
AstraZeneca PLC обнаруживает, разрабатывает, производит и продает рецептурные лекарства в области онкологии, сердечно-сосудистой системы, почек и обмена веществ, респираторных заболеваний, инфекций, нейробиологии и гастроэнтерологии по всему миру. more detailsMain settings
ISIN
GB0009895292
Industry
Pharmaceuticals
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
2.07
Дивиденд ао
3.11
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 3.76 | 4 |
| P/BV | 4.98 | 3 |
| P/E | 28.91 | 6 |
Efficiency
| Title | Value | Grade |
| ROA | 6.86 | 2 |
| ROE | 17.6 | 5 |
| ROIC | -0.09 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 1.93 | 4.83 |
| DSI | 0.7857 | 7.86 |
| Average dividend growth | 2.14 | 3.57 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 1.76 | 7 |
| Debt/Ratio | 0.2895 | 10 |
| Debt/Equity | 1.55 | 7 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 103.15 | 10 |
| Yield Ebitda, % | 105.36 | 10 |
| Yield EPS, % | 84.58 | 9 |
Dividends
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 150.11 $ | 0 $ | 0 $ | -0 % | 0 % | 0 % |
| Week | 144.32 $ | 148.21 $ | 150.1 $ | 4 % | 0 % | 0 % |
| Month | 141.12 $ | 138.24 $ | 150.1 $ | 6.36 % | 0 % | 0 % |
| Three month | 129.16 $ | 128.91 $ | 154.64 $ | 16.21 % | 0 % | 0 % |
| Half a year | 139.54 $ | 128.91 $ | 157.58 $ | 7.57 % | 0 % | 0 % |
| Year | 171 $ | 124.7 $ | 175 $ | -12.22 % | 0 % | 0 % |
| 3 years | 126.59 $ | 104.5 $ | 175 $ | 18.57 % | 0 % | 0 % |
| 5 years | 110.05 $ | 94.71 $ | 175 $ | 36.39 % | 0 % | 0 % |
| 10 years | 0 $ | 49.89 $ | 175 $ | 0 % | 0 % | 0 % |
| Year to date | 148.94 $ | 128.91 $ | 157.58 $ | 0.78 % | 0 % | 0 % |
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
FinEx Ex-USA ETF USD
|
1.6 | 45.15 | 0.9 |
| 1.6 | 45.15 | 0.9 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Executive Director | 5.76M | 1959 (66 years) |
| Dr. Aradhana Sarin M.D. | CFO & Executive Director | 3.18M | 1974 (51 year) |
| Ms. Pam P. Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | N/A | 1970 (55 years) |
| Mr. Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | N/A | |
| Gonzalo Vina | Head of Global Media Relations | N/A | |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit | N/A | |
| Mr. Andrew P. Barnett | Head of Investor Relations | N/A | |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development | N/A | 1966 (59 years) |
| Mr. Leon Wang | Executive VP of International & China President | N/A | |
| Ms. Iskra Reic | Executive Vice-President of Vaccines & Immune Therapies |
About company
Address: United Kingdom, Cambridge CB AA, 1 Francis Crick Avenue - Open in google maps, Open in yandex maps
Website: https://www.astrazeneca.com
Website: https://www.astrazeneca.com
